GlassScriptPhysician profile
Hadeel Barrawi
NPI 1366063927
$1,647.29
in general payments reported to CMS, 2019-2025
22 companies · $514 in 2025
The $514 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $326 · 2022: $97.43 · 2023: $219 · 2024: $491 · 2025: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,224.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $173.83 | 2023-2025 | |
| Novo Nordisk INC | $168.84 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Dexcom, INC. | $146.89 | 2021-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $142.43 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $135.57 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Otsuka America Pharmaceutical, INC. | $133.99 | 2022-2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $116.13 | 2021-2025 | Spravato |
| Neurocrine Biosciences, INC. | $102.08 | 2021 | |
| Exact Sciences Corporation | $84.56 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $73.92 | 2024-2025 | |
| Amgen INC. | $63.95 | 2023-2025 | Otezla, Repatha, Otezla |
| Axsome Therapeutics, INC. | $53.55 | 2025 | Symbravo, Auvelity |
| Astrazeneca Pharmaceuticals LP | $40.31 | 2024 | Farxiga, Airsupra |
| Corcept Therapeutics | $39.78 | 2025 | Korlym |
| Acadia Pharmaceuticals INC | $32.48 | 2024 | Daybue |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.75 | 2024 | Jardiance |
| Boston Scientific Corporation | $20.93 | 2021 | |
| Inspire Medical Systems, INC. | $19.93 | 2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $19.80 | 2025 | |
| Medtronic, INC. | $15.98 | 2025 | Intellis Adaptivestim |
| Nevro Corp. | $15.94 | 2024 | Senza |
| Biogen, INC. | $15.65 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hadeel Barrawi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.